Raises FY26 revenue to $3.05B-$3.15B from $3.05B-$3.15B. Consensus is for FY26 EPS 99c and for revenue $3.1B. Reaffirms FY26 CapEx view $110M.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals reports Q1 adjusted EPS 27c, consensus 17c
- Amneal announces additional interim Phase 4 ELEVATE-PD study results
- Amneal Pharmaceuticals initiated with a Buy at UBS
- Amneal announces U.S. launch of two respiratory metered-dose inhalation products
- Amneal Pharmaceuticals Earnings Call: Growth Amid Transition